These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
324 related articles for article (PubMed ID: 31575540)
1. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma. Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540 [TBL] [Abstract][Full Text] [Related]
2. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma. Kim RD; Sarker D; Meyer T; Yau T; Macarulla T; Park JW; Choo SP; Hollebecque A; Sung MW; Lim HY; Mazzaferro V; Trojan J; Zhu AX; Yoon JH; Sharma S; Lin ZZ; Chan SL; Faivre S; Feun LG; Yen CJ; Dufour JF; Palmer DH; Llovet JM; Manoogian M; Tugnait M; Stransky N; Hagel M; Kohl NE; Lengauer C; Sherwin CA; Schmidt-Kittler O; Hoeflich KP; Shi H; Wolf BB; Kang YK Cancer Discov; 2019 Dec; 9(12):1696-1707. PubMed ID: 31575541 [TBL] [Abstract][Full Text] [Related]
3. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043 [TBL] [Abstract][Full Text] [Related]
4. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma. Tao Z; Cui Y; Xu X; Han T Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2208844119. PubMed ID: 36179047 [TBL] [Abstract][Full Text] [Related]
5. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report. Gao L; Shay C; Lv F; Wang X; Teng Y Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785 [TBL] [Abstract][Full Text] [Related]
6. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529 [TBL] [Abstract][Full Text] [Related]
7. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4. Chen J; Du F; Dang Y; Li X; Qian M; Feng W; Qiao C; Fan D; Nie Y; Wu K; Xia L Hepatology; 2020 May; 71(5):1712-1731. PubMed ID: 31529503 [TBL] [Abstract][Full Text] [Related]
8. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential. Xie H; Alem Glison DM; Kim RD Expert Opin Investig Drugs; 2022 Apr; 31(4):393-400. PubMed ID: 34913780 [TBL] [Abstract][Full Text] [Related]
9. FGF19- Raja A; Park I; Haq F; Ahn SM Cells; 2019 Jun; 8(6):. PubMed ID: 31167419 [TBL] [Abstract][Full Text] [Related]
10. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. Lu X; Chen H; Patterson AV; Smaill JB; Ding K J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487 [TBL] [Abstract][Full Text] [Related]
11. EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma. Shen B; Shi JP; Zhu ZX; He ZD; Liu SY; Shi W; Zhang YX; Ying HY; Wang J; Xu RF; Fang F; Chang HX; Chen Z; Zhang NN Mol Cancer Ther; 2023 Dec; 22(12):1479-1492. PubMed ID: 37710057 [TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). Li W; Sparidans R; El-Lari M; Wang Y; Lebre MC; Beijnen JH; Schinkel AH Int J Pharm; 2020 Jan; 573():118842. PubMed ID: 31759109 [TBL] [Abstract][Full Text] [Related]
13. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations. Mellor HR Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342 [TBL] [Abstract][Full Text] [Related]
14. FGF19 Protects Hepatocellular Carcinoma Cells against Endoplasmic Reticulum Stress via Activation of FGFR4-GSK3β-Nrf2 Signaling. Teng Y; Zhao H; Gao L; Zhang W; Shull AY; Shay C Cancer Res; 2017 Nov; 77(22):6215-6225. PubMed ID: 28951455 [TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. Ho HK; Pok S; Streit S; Ruhe JE; Hart S; Lim KS; Loo HL; Aung MO; Lim SG; Ullrich A J Hepatol; 2009 Jan; 50(1):118-27. PubMed ID: 19008009 [TBL] [Abstract][Full Text] [Related]
16. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2. Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560 [TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4. Shao M; Chen X; Yang F; Song X; Zhou Y; Lin Q; Fu Y; Ortega R; Lin X; Tu Z; Patterson AV; Smaill JB; Chen Y; Lu X J Med Chem; 2022 Mar; 65(6):5113-5133. PubMed ID: 35271262 [TBL] [Abstract][Full Text] [Related]
18. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma. Kanzaki H; Chiba T; Ao J; Koroki K; Kanayama K; Maruta S; Maeda T; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Ogasawara S; Suzuki E; Ooka Y; Muroyama R; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Mimura N; Kato J; Zen Y; Ohtsuka M; Iwama A; Kato N Sci Rep; 2021 Mar; 11(1):5303. PubMed ID: 33674622 [TBL] [Abstract][Full Text] [Related]
19. FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation. Zhao H; Lv F; Liang G; Huang X; Wu G; Zhang W; Yu L; Shi L; Teng Y Oncotarget; 2016 Mar; 7(12):13575-86. PubMed ID: 26498355 [TBL] [Abstract][Full Text] [Related]
20. FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling. Yang Y; Zhang Y; Cao J; Su Z; Li F; Zhang P; Zhang B; Liu R; Zhang L; Xie J; Li J; Zhang J; Chen X; Hong A J Exp Clin Cancer Res; 2023 Apr; 42(1):96. PubMed ID: 37085881 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]